Infliximab Inhibits Activation and Effector Functions of Peripheral Blood T Cells in vitro from Patients with Clinically Active Ulcerative Colitis

Scandinavian Journal of Immunology

Volumn 78, Issue 3, 2013, Pages 275-284

  Dahlen R ^a   Strid, H ^a   Lundgren, A ^a   Isaksson, S ^a   Raghavan, S ^a   Magnusson, M K ^a   Simren M ^a   Sjovall H ^a   Ohman L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COLITIS, ULCERATIVE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRANZYMES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-13; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; TUMOR NECROSIS FACTORS; YOUNG ADULT;

EID: 84883026168     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12081     Document Type: Article

References (28)

1. Fuss IJ, Neurath M, Boirivant M et al. Disparate CD4 + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-70.
2. Heller F, Florian P, Bojarski C et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64.
3. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117:514-21.
4. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126:1582-92.
5. Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
6. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
7. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501.
8. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
9. Aspalter RM, Eibl MM, Wolf HM. Regulation of TCR-mediated T cell activation by TNF-RII. J Leukoc Biol 2003;74:572-82.
10. Lugering A, Schmidt M, Lugering N et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
11. Di Sabatino A, Ciccocioppo R, Cinque B et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004;53:70-7.
12. ten Hove T, van Montfrans C, Peppelenbosch MP et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
13. Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.
14. Ringheanu M, Daum F, Markowitz J et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 2004;10:801-10.
15. Ebert EC. Infliximab and the TNF-alpha system. Am J Physiol Gastrointest Liver Physiol 2009;296:G612-20.
16. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007;204:33-9.
17. Boschetti G, Nancey S, Sardi F et al. Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:160-70.
18. Li Z, Arijs I, De Hertogh G et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis 2010;16:1299-310.
19. Dige A, Hvas CL, Deleuran B et al. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells. Scand J Gastroenterol 2011;46:1206-14.
20. Hvas CL, Kelsen J, Agnholt J et al. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease. Autoimmunity 2010;43:325-33.
21. Ferrante M, Vermeire S, Katsanos KH et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:123-8.
22. Pimentel-Muinos FX, Munoz-Fernandez MA, Fresno M. Control of T lymphocyte activation and IL-2 receptor expression by endogenously secreted lymphokines. J Immunol 1994;152:5714-22.
23. Baert FJ, D'Haens GR, Peeters M et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
24. Olsen T, Cui G, Goll R et al. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 2009;44:727-35.
25. Thaher F, Plankenhorn S, Klein R. Differential effects of the tumor necrosis factor alpha-blocker infliximab and etanercept on immunocompetent cells in vitro. Int Immunopharmacol 2011;11:1724-31.
26. Rismo R, Olsen T, Cui G et al. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol 2012;47:538-47.
27. Goldstein I, Ben-Horin S, Koltakov A et al. alpha1beta1 Integrin+ and regulatory Foxp3 + T cells constitute two functionally distinct human CD4 + T cell subsets oppositely modulated by TNFalpha blockade. J Immunol 2007;178:201-10.
28. Bedini C, Nasorri F, Girolomoni G et al. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4 + and CD8 + T lymphocytes and impairs dendritic cell function. Br J Dermatol 2007;157:249-58.